Carboplatin, an analogue of "classical" cis-diamminedichloridoplatinum(II) (cisplatin), is a widely used second-generation platinum anticancer drug. Cytotoxicity of cisplatin and carboplatin is mediated by platinum-DNA adducts. Markedly higher concentrations of carboplatin are required, and the rate of adduct formation is considerably slower. The reduced toxic effects in tumor cells and a more acceptable side-effect profile are attributable to the lower reactivity of carboplatin with nucleophiles, since the cyclobutanedicarboxylate ligand is a poorer leaving group than the chlorides in cisplatin. Recently, platinum complexes were shown to be particularly attractive as potential photochemotherapeutic anticancer agents. Selective photoactivation of platinum complexes by irradiation of cancer cells may avoid enhancement of toxic side-effects, but may increase toxicity selectively in cancer cells and extend the application of photoactivatable platinum complexes to resistant cells and to a wider range of cancer types. Therefore, it was of interest to examine whether carboplatin can be affected by irradiation with light to the extent that its DNA binding and cytotoxic properties are altered. We have found that carboplatin is converted to species capable of enhanced DNA binding by UVA irradiation and consequently its toxicity in cancer cells is markedly enhanced. Recent advances in laser and fiber-optic technologies make it possible to irradiate also internal organs with light of highly defined intensity and wavelength. Thus, carboplatin is a candidate for use in photoactivated cancer chemotherapy.

Department of Biophysics Faculty of Science Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Biochemistry. 1999 May 25;38(21):6781-90 PubMed

Cancer Invest. 2001;19(7):756-60 PubMed

Biochemistry. 1990 Oct 16;29(41):9522-31 PubMed

Cancer Res. 1993 Dec 1;53(23):5669-75 PubMed

Biochem Pharmacol. 1999 Nov 15;58(10):1625-9 PubMed

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20743-8 PubMed

Mol Cancer Ther. 2009 Jan;8(1):10-6 PubMed

Nat Rev Cancer. 2007 Aug;7(8):573-84 PubMed

Chem Rev. 1999 Sep 8;99(9):2467-98 PubMed

Nucleic Acids Res. 1996 Jan 15;24(2):336-41 PubMed

Eur J Biochem. 1977 Sep;78(2):455-63 PubMed

Oncol Rep. 2003 Nov-Dec;10(6):1663-82 PubMed

Biochem Pharmacol. 1993 Oct 19;46(8):1377-83 PubMed

Prog Nucleic Acid Res Mol Biol. 2002;71:1-68 PubMed

Biochem Pharmacol. 2004 Mar 15;67(6):1097-109 PubMed

J Neurol Neurosurg Psychiatry. 1998 May;64(5):667-9 PubMed

Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 PubMed

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5345-9 PubMed

Br J Cancer. 1991 Feb;63(2):195-200 PubMed

Eur J Biochem. 1991 Dec 18;202(3):975-80 PubMed

Chemistry. 2007;13(36):10108-16 PubMed

Ann Oncol. 1991 Feb;2(2):115-21 PubMed

Biochemistry. 1995 Jul 4;34(26):8474-80 PubMed

Chemistry. 2009 Jun 15;15(25):6211-21 PubMed

Cancer Res. 1986 Apr;46(4 Pt 2):1972-9 PubMed

J Med Chem. 2008 Sep 11;51(17):5310-9 PubMed

Eur J Biochem. 1998 Jun 15;254(3):547-57 PubMed

Biochemistry. 1985 Jan 29;24(3):707-13 PubMed

Anticancer Agents Med Chem. 2007 Jan;7(1):75-93 PubMed

J Inorg Biochem. 2003 Dec 1;97(4):354-63 PubMed

Chem Res Toxicol. 2012 Feb 20;25(2):500-9 PubMed

J Med Chem. 2006 Dec 28;49(26):7792-8 PubMed

Biophysik. 1970;6(4):290-300 PubMed

Biochem Pharmacol. 2010 Jan 15;79(2):112-21 PubMed

Potentiating effect of UVA irradiation on anticancer activity of Carboplatin derivatives involving 7-azaindoles